Table 3.
Results of plaque reduction neutralization tests with selected Candiru complex phleboviruses
| Virus | Clade on segment M | Antiserum dilutiona |
|||||
|---|---|---|---|---|---|---|---|
| Clade A |
Clade B, Itaituba | Clade C, Oriximina | |||||
| Candiru | Alenquer | Nique | Turuna | ||||
| Candiru | A | 1,280 | <10 | <10 | 10 | <10 | <10 |
| Alenquer | A | <10 | 80 | <10 | <10 | <10 | <10 |
| Nique | A | 40 | <10 | 80 | 20 | <10 | <10 |
| Turuna | A | 320 | <10 | 40 | 1,280 | <10 | 40 |
| Itaituba | B | 640 | <10 | 640 | <10 | 5,120 | 160 |
| Oriximina | C | 320 | 20 | 160 | 20 | 160 | 160 |
a
Reciprocal of highest antiserum dilution producing 90% plaque inhibition.